$1.00
0.00%
Nasdaq, Sep 17, 10:44 am EDT. Closed.
ISIN
US9186401033
Symbol
VCNX

Vaccinex, Inc. Stock price

$1.00
+0.22 28.88% 1M
-0.09 8.26% 6M
-0.08 7.02% YTD
+0.32 47.06% 1Y
-35.58 97.27% 3Y
-477.80 99.79% 5Y
-2,388.80 99.96% 10Y
-2,388.80 99.96% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
+0.00 0.00%
ISIN
US9186401033
Symbol
VCNX
Industry

Is Vaccinex, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$2.7m
Enterprise Value
$1.6m
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
negative
P/S
4.5 | -
EV/Sales
2.7 | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-95.8%
Return on Equity
749.0%
ROCE
-
ROIC
-
Debt/Equity
-
Financials (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-
EBIT
-
Net Income
-
Free Cash Flow
-
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
-
FCF per Share
-
Short interest
3.2%
Employees
25
Rev per Employee
$20.0k

Vaccinex, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Vaccinex, Inc. forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Vaccinex, Inc. forecast:

Buy
86%
Hold
14%

Financial data from Vaccinex, Inc.

Dec '24
+/-
%
0.60 0.60
5% 5%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 6.79 6.79
1% 1%
1,132%
- Research and Development Expense 13 13
24% 24%
2,092%
-19 -19
18% 18%
-3,107%
- Depreciation and Amortization 0.09 0.09
25% 25%
15%
EBIT (Operating Income) EBIT -19 -19
18% 18%
-3,123%
Net Profit -19 -19
8% 8%
-3,105%

In millions USD.

Don't miss a Thing! We will send you all news about Vaccinex, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Vaccinex, Inc. Stock News

Neutral
GlobeNewsWire
5 months ago
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer's, Huntington's disease, and cancer today released financial results for the year ended December 31, 2025. The financial statements have been posted on the company website.

Company Profile

Vaccinex, Inc. is a clinical-stage biotechnology company, which engages in the development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. The firm focuses in the development of pepinemab for the treatment of non-small cell lung cancer, or NSCLC, osteosarcoma, melanoma and Huntington's disease. Its products pipeline includes SEMA4D antibody platform and ActivMAb antibody discovery platform. The company was founded by Maurice Zauderer and Deepak Sahasrabudhe in 1997 and is headquartered in Rochester, NY.

Head office United States
CEO Dr. Zauderer
Employees 25
Founded 1997
Website www.vaccinex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today